Anna Markowska1, Monika Szarszewska2, Pawel Knapp3, Anna Grybos4, Marian Grybos5, Andrzej Marszalek6, Violetta Filas6, Katarzyna Wojcik-Krowiranda7, Malgorzata Swornik8, Janina Markowska9. 1. Department of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznan, Poland. 2. Department of Oncology, Gynaecological Oncology, Poznan University of Medical Sciences, Poznan, Poland. monika.szarszewska@gmail.com. 3. Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, Bialystok, Poland. 4. Department of Gyneacology and Obstetrics, Faculty of Health Science, Wroclaw Medical University, Wroclaw, Poland. 5. Medical School in Opole, Opole, Poland. 6. Department of Tumour Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland. 7. Medical University of Lodz, Gynecological-Oncology, Lodz, Poland. 8. Gynecological Endocrinology Department, Jagiellonian University Medical College, Krakow, Poland. 9. Department of Oncology, Gynaecological Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Abstract
OBJECTIVES: Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET and ARID1A are also related to prognosis in endometrial cancer. MATERIAL AND METHODS: Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF1, MLH1, MSH2,c-MET and ARID1A were examined. RESULTS: In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of NESF-1 in type II EC. In type I EC, NESF-1 expression was significantly higher in G1 in comparison to G2 and G3 together. A significantly lower expression of MLH1 was demonstrated in type I EC. CONCLUSIONS: The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency was detected for a high expression of NESF-1 in patients with type II EC, who also exhibited a high expression of MSH2.
OBJECTIVES:Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET and ARID1A are also related to prognosis in endometrial cancer. MATERIAL AND METHODS: Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF1, MLH1, MSH2,c-MET and ARID1A were examined. RESULTS: In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of NESF-1 in type II EC. In type I EC, NESF-1 expression was significantly higher in G1 in comparison to G2 and G3 together. A significantly lower expression of MLH1 was demonstrated in type I EC. CONCLUSIONS: The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency was detected for a high expression of NESF-1 in patients with type II EC, who also exhibited a high expression of MSH2.
Entities:
Keywords:
ARID1A; MLH1; MSH2; NESF-1; c-MET; endometrial cancer